109 related articles for article (PubMed ID: 19572549)
1. Identification of inhibitors of checkpoint kinase 1 through template screening.
Matthews TP; Klair S; Burns S; Boxall K; Cherry M; Fisher M; Westwood IM; Walton MI; McHardy T; Cheung KM; Van Montfort R; Williams D; Aherne GW; Garrett MD; Reader J; Collins I
J Med Chem; 2009 Aug; 52(15):4810-9. PubMed ID: 19572549
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.
Oza V; Ashwell S; Brassil P; Breed J; Deng C; Ezhuthachan J; Haye H; Horn C; Janetka J; Lyne P; Newcombe N; Otterbien L; Pass M; Read J; Roswell S; Su M; Toader D; Yu D; Yu Y; Valentine A; Webborn P; White A; Zabludoff S; Zheng X
Bioorg Med Chem Lett; 2010 Sep; 20(17):5133-8. PubMed ID: 20673630
[TBL] [Abstract][Full Text] [Related]
3. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
[TBL] [Abstract][Full Text] [Related]
4. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
[TBL] [Abstract][Full Text] [Related]
7. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
9. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.
Foloppe N; Fisher LM; Howes R; Potter A; Robertson AG; Surgenor AE
Bioorg Med Chem; 2006 Jul; 14(14):4792-802. PubMed ID: 16574416
[TBL] [Abstract][Full Text] [Related]
10. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic EJ; Garbaccio RM; Fraley ME; Tasber ES; Steen JT; Arrington KL; Dudkin VY; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2007 Nov; 17(21):5989-94. PubMed ID: 17804227
[TBL] [Abstract][Full Text] [Related]
11. A robust, target-driven, cell-based assay for checkpoint kinase 1 inhibitors.
Ish T; Sootome H; King AJ; Suda M; Noro N; Yamashita K; Noumi T; Ishii T
J Biomol Screen; 2007 Sep; 12(6):809-17. PubMed ID: 17517898
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.
Tong Y; Claiborne A; Stewart KD; Park C; Kovar P; Chen Z; Credo RB; Gu WZ; Gwaltney SL; Judge RA; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
Bioorg Med Chem; 2007 Apr; 15(7):2759-67. PubMed ID: 17287122
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.
Foloppe N; Fisher LM; Howes R; Kierstan P; Potter A; Robertson AG; Surgenor AE
J Med Chem; 2005 Jun; 48(13):4332-45. PubMed ID: 15974586
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.
Tao ZF; Li G; Tong Y; Stewart KD; Chen Z; Bui MH; Merta P; Park C; Kovar P; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5944-51. PubMed ID: 17827013
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.
Kumar V; Khan S; Gupta P; Rastogi N; Mishra DP; Ahmed S; Siddiqi MI
J Comput Aided Mol Des; 2014 Dec; 28(12):1247-56. PubMed ID: 25312395
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.
Huang X; Cheng CC; Fischmann TO; Duca JS; Richards M; Tadikonda PK; Reddy PA; Zhao L; Siddiqui MA; Parry D; Davis N; Seghezzi W; Wiswell D; Shipps GW
Bioorg Med Chem Lett; 2013 May; 23(9):2590-4. PubMed ID: 23535330
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927
[TBL] [Abstract][Full Text] [Related]
18. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
[TBL] [Abstract][Full Text] [Related]
19. Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates.
Dudkin VY; Rickert K; Kreatsoulas C; Wang C; Arrington KL; Fraley ME; Hartman GD; Yan Y; Ikuta M; Stirdivant SM; Drakas RA; Walsh ES; Hamilton K; Buser CA; Lobell RB; Sepp-Lorenzino L
Bioorg Med Chem Lett; 2012 Apr; 22(7):2609-12. PubMed ID: 22374217
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
